Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Rabbit Polyclonal (IgG) to Human ACY1 / Aminoacylase 1
IHC, Immunofluorescence, Western blot
Rat Monoclonal (IgG2b) to Mouse ACY1 / Aminoacylase 1
Western blot, Immunoprecipitation, ELISA
Mouse ACY1 / Aminoacylase 1
Mouse (tested or 100% immunogen sequence identity)
Rat (at least 90% immunogen sequence identity)
Protein G purified
Western blot (1 - 2 µg/ml)
Immunoprecipitation (25 µg/ml)
ELISA (0.5 - 1 µg/ml)
Specificity and Use
NS0-derived rmACY1 (aa 1 - 408).
Recognizes mouse ACY1.
Suitable for use in Direct ELISA, Western Blot and Immunoprecipitation. Direct ELISA: 0.5-1.0 ug/ml detection limit for rmACY1 is ~2 ng/well. Western Blot: 1-2 ug/ml detection limit for rmACY1 is ~10 ng/lane under non-reducing and reducing conditions. Immunoprecipitation: 25 ug/mL to immunoprecipitate rmACY1 from cell lysate.
Lyophilized from PBS, 5% trehalose. Reconstitute with200 ul sterile 40-50% glycerol, PBS.
100 µl PBS, 40-50% glycerol
+4°C or -20°C, Avoid repeated freezing and thawing.
ACY1 / Aminoacylase 1 is a cytosolic, homodimeric, zinc-binding enzyme that catalyzes the hydrolysis of acylated L-amino acids to L-amino acids and an acyl group, and has been postulated to function in the catabolism and salvage of acylated amino acids. This gene is located on chromosome 3p21.1, a region reduced to homozygosity in small-cell lung cancer (SCLC), and its expression has been reported to be reduced or undetectable in SCLC cell lines and tumors.